Phaseline

Companies › Fujian Akeylink Biotechnology

Fujian Akeylink Biotechnology: clinical trials, targets and expected readouts

2 active drug programs in 4 registered trials: 3 Phase 2, 1 Phase 3; Infectious disease; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
GST-HG141
HBV capsid assembly modulator (CAM) with distinct antiviral mechanism
–Phase 3Chronic Hepatitis b; Chronic Hepatitis BDec 2026
GST-HG131
Dihydroquinolizinone compound that reduces circulating HBsAg levels
–Phase 2Chronic Hepatitis BDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06263959GST-HG131Phase 2Chronic Hepatitis BInfectious diseaseApr 2025
NCT07090759GST-HG141Phase 3Chronic Hepatitis bInfectious diseaseDec 2026
NCT07709520GST-HG141Phase 2Chronic Hepatitis BInfectious diseaseDec 2026
NCT07709520GST-HG131Phase 2Chronic Hepatitis BInfectious diseaseDec 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Ausper Biopharma Suzhou HepaThera Biotech TaiMed Biologics Labo'Life Laboratorio Farmaceutico SIT srl

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.